These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33712376)

  • 1. Episodic Memory-Related Imaging Features as Valuable Biomarkers for the Diagnosis of Alzheimer's Disease: A Multicenter Study Based on Machine Learning.
    Shi Y; Wang Z; Chen P; Cheng P; Zhao K; Zhang H; Shu H; Gu L; Gao L; Wang Q; Zhang H; Xie C; Liu Y; Zhang Z;
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2023 Feb; 8(2):171-180. PubMed ID: 33712376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Radiomic Features as New Biomarkers for Alzheimer's Disease: An Amyloid PET Study.
    Ding Y; Zhao K; Che T; Du K; Sun H; Liu S; Zheng Y; Li S; Liu B; Liu Y;
    Cereb Cortex; 2021 Jul; 31(8):3950-3961. PubMed ID: 33884402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rey's Auditory Verbal Learning Test scores can be predicted from whole brain MRI in Alzheimer's disease.
    Moradi E; Hallikainen I; Hänninen T; Tohka J;
    Neuroimage Clin; 2017; 13():415-427. PubMed ID: 28116234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort.
    Alegret M; Sotolongo-Grau O; de Antonio EE; Pérez-Cordón A; Orellana A; Espinosa A; Gil S; Jiménez D; Ortega G; Sanabria A; Roberto N; Hernández I; Rosende-Roca M; Tartari JP; Alarcon-Martin E; de Rojas I; Montrreal L; Morató X; Cano A; Rentz DM; Tárraga L; Ruiz A; Valero S; Marquié M; Boada M
    Alzheimers Res Ther; 2022 Mar; 14(1):43. PubMed ID: 35303916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer's Disease Spectrum.
    Massetti N; Russo M; Franciotti R; Nardini D; Mandolini GM; Granzotto A; Bomba M; Delli Pizzi S; Mosca A; Scherer R; Onofrj M; Sensi SL; ;
    J Alzheimers Dis; 2022; 85(4):1639-1655. PubMed ID: 34958014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing different algorithms for the course of Alzheimer's disease using machine learning.
    Tang X; Liu J
    Ann Palliat Med; 2021 Sep; 10(9):9715-9724. PubMed ID: 34628897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing forgetfulness: can episodic-memory tests predict early Alzheimer's disease?
    Warren SL; Moustafa AA; Alashwal H;
    Exp Brain Res; 2021 Sep; 239(9):2925-2937. PubMed ID: 34313791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
    Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
    J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S; Passamonti L; Duggento A; Liò P; Toschi N;
    Neuroimage; 2019 Apr; 189():276-287. PubMed ID: 30654174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.